Despite the 7:00am Sunday start, the room was packed, reflecting clinicians’ strong commitment to staying informed about the latest developments in ITP care.
The program featured leading medical advisors, including Dr Robert Bird, Dr Danny Hsu, Dr Sara Ng, and Dr Phil Choi, who presented on topics ranging from clinical trials and managing menorrhagia in ITP to combination strategies for refractory disease. The session concluded with a lively Q&A, giving attendees the chance to engage directly with experts. The atmosphere was collaborative and energised, with participants leaving better equipped to support patients through evidence-based practice.
“ITPANZ truly offers a full 360 support system ensuring that all key stakeholders are informed and supported when it comes to Immune Thrombocytopenia.”
ITPANZ extends sincere thanks to Sanofi, Novartis and Amgen for their generous support of the 2025 ITP Breakfast Meeting. Their involvement ensures that healthcare professionals continue to receive the education and resources needed to improve patient outcomes.
This event launched ITPANZ at the annual Haematology Conference, BLOOD 2025, attended by more than 4,000 delegates. At the ITPANZ booth, attendees were invited to read real patients and healthcare professionals’ statements and reflect on them.
We then asked three questions, including “What surprised you most about these statements?” “What will you do differently after today?” and “What do you want patients to know when they’re with you?” encourage deeper thinking about the lived experience of ITP.
“I want all my patients to feel empowered by the next steps or decisions we make together.”
“I will supply more information and education & make sure they feel safe and comfortable.”
The overwhelming responses included shock and disbelief with many clinicians calling for greater empathy from their colleagues. Once they’d participated, they all proudly wore their ITPANZ badges ‘I listened to an ITP Patient Today’, ‘ITP Care is a Shared Decision’ and ‘Listening leads to better ITP Care’, while enjoying a light-hearted scavenger hunt that included selfies with medical advisors and fun opportunities to learn more about ITP and it real-world impacts on patients.
Feedback from BLOOD 2025 was overwhelmingly positive.
Attendees valued the interactive booth and the opportunity to engage with patient perspectives. The event highlighted the importance of recognising ITP as a serious condition that impacts both physical and mental health. It reinforced ITPANZ’s role as the peak body advocating for patients across Australia and New Zealand.
Together, the ITP Breakfast Meeting and Blood 2025 showcased how education, collaboration, and patient voices drive progress. These events remind us that while treatments and trials are vital, the lived experience of patients must remain at the centre of care.
